Skip to main content

Find Clinical Trials

Home
Conditions
EGFR-TKI Sensitizing Mutation

Clinical trial condition

EGFR-TKI Sensitizing Mutation

Explore clinical trials studying EGFR-TKI Sensitizing Mutation. Study availability and eligibility vary by location and protocol.

4 public trials 1 recruiting study

Refine in advanced search Browse all conditions

EGFR-TKI Sensitizing Mutation trial results

Recruiting

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

NCT01994057

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +12 more
Locations: Cancer Center, Sun Yat-sen University Guangzhou, Guangdong, China

View Trial Details

Not Yet Recruiting

Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI

NCT07551414

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +16 more
Locations: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing, China

View Trial Details

Not Yet Recruiting

Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg

NCT07298148

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +10 more
Locations: Not specified

View Trial Details

Completed

First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer

NCT06521034

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +10 more
Locations: Yongchang Zhang Changsha, Hunan, China

View Trial Details